Arrhythmias & electrophysiology
Heart transplantation for pediatric patients with malignant arrhythmias: Indications and outcomes
Authors' conclusion
Their waitlist mortality and posttransplant outcomes were comparable to those of the non-MA cohort.
Study context
- Population
- Patients <18 years listed for HTX, Pediatric Heart Transplant Society registry, 2014–20223,317 transplanted
- Participants
- 4,630 patients
- Exposure
- Malignant arrhythmia (MA) vs non-MA listing indication
- MAn = 63
- Outcome
- Outcomes of pediatric patients listed for HTX with MA:
- Waitlist mortality
- Transplantation
- Posttransplant survival
- Freedom from rejection
Methodological detailsprospective registry
- Prospective registry
Main finding
As reported in the abstract
Outcomes vs non-MA
- Waitlist mortality, transplantation, posttransplant survival and freedom from rejection comparable to non-MA
Observational data: associations, not effects.
Further findings
Age at listing
P < 0.01
Presentation with cardiac arrest
P < 0.01
In ICU at listing
P < 0.01
On inotropes at listing
P < 0.01
- MA as indication
- 1.4% · 63
MA categories
- Primary tachyarrhythmia (PT)
- 11 (17%)
- Inherited arrhythmia (IA)
- 4 (6%)
- Congenital heart disease
- 6 (10%)
- Cardiomyopathy (CM)
- 42 (67%)
Original publication
Heart transplantation for pediatric patients with malignant arrhythmias: Indications and outcomes. Heart Rhythm. Published 9 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →